Biopharma Closely Watching Biden’s Pick For The Next FDA Commissioner – With Biogen Having The Most At Stake If approved, biopharmaceutical critics will accuse the F.D.A. of being too closely aligned with industry. If rejected, the F.D.A will be attacked by patients and advocacy groups as preventing access to a much needed new medicine.